167 related articles for article (PubMed ID: 28763344)
1. The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine.
Sarfati D; Evans VC; Tam EM; Woo C; Iverson GL; Yatham LN; Lam RW
Int Clin Psychopharmacol; 2017 Nov; 32(6):343-349. PubMed ID: 28763344
[TBL] [Abstract][Full Text] [Related]
2. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder.
Lam RW; Iverson GL; Evans VC; Yatham LN; Stewart K; Tam EM; Axler A; Woo C
J Affect Disord; 2016 Oct; 203():55-61. PubMed ID: 27280963
[TBL] [Abstract][Full Text] [Related]
3. Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis.
Lam RW; Wajsbrot DB; Meier E; Pappadopulos E; Mackell JA; Boucher M
J Psychopharmacol; 2017 Sep; 31(9):1204-1214. PubMed ID: 28718346
[TBL] [Abstract][Full Text] [Related]
4. Relationship between work functioning and self-reported cognitive complaints in patients with major depressive disorder treated with desvenlafaxine.
Alonso-Prieto E; Rubino C; Lucey M; Evans VC; Tam EM; Woo C; Iverson GL; Chakrabarty T; Yatham LN; Lam RW
Psychiatry Res; 2019 Feb; 272():144-148. PubMed ID: 30583256
[TBL] [Abstract][Full Text] [Related]
5. Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine.
Lam RW; Endicott J; Hsu MA; Fayyad R; Guico-Pabia C; Boucher M
Int Clin Psychopharmacol; 2014 Sep; 29(5):239-51. PubMed ID: 24583567
[TBL] [Abstract][Full Text] [Related]
6. The effect of remission status on work functioning in employed patients treated for major depressive disorder.
Sarfati D; Stewart K; Woo C; Parikh SV; Yatham LN; Lam RW
Ann Clin Psychiatry; 2017 Feb; 29(1):11-16. PubMed ID: 27901522
[TBL] [Abstract][Full Text] [Related]
7. Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis.
Katzman MA; Wang X; Wajsbrot DB; Boucher M
J Psychopharmacol; 2020 Mar; 34(3):280-292. PubMed ID: 31913085
[TBL] [Abstract][Full Text] [Related]
8. An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder.
Carrasco JL; Kornstein SG; McIntyre RS; Fayyad R; Prieto R; Salas M; Mackell J; Boucher M
Int Clin Psychopharmacol; 2016 May; 31(3):134-46. PubMed ID: 26895080
[TBL] [Abstract][Full Text] [Related]
9. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.
Dunlop BW; Reddy S; Yang L; Lubaczewski S; Focht K; Guico-Pabia CJ
J Clin Psychopharmacol; 2011 Oct; 31(5):569-76. PubMed ID: 21869698
[TBL] [Abstract][Full Text] [Related]
10. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
Soares CN; Kornstein SG; Thase ME; Jiang Q; Guico-Pabia CJ
J Clin Psychiatry; 2009 Oct; 70(10):1365-71. PubMed ID: 19906341
[TBL] [Abstract][Full Text] [Related]
11. The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial.
Reddy S; Fayyad R; Edgar CJ; Guico-Pabia CJ; Wesnes K
J Psychopharmacol; 2016 Jun; 30(6):559-67. PubMed ID: 27009044
[TBL] [Abstract][Full Text] [Related]
12. Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder.
Endicott J; Lam RW; Hsu MA; Fayyad R; Boucher M; Guico-Pabia CJ
J Affect Disord; 2014 Sep; 166():307-14. PubMed ID: 25012446
[TBL] [Abstract][Full Text] [Related]
13. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.
Papakostas GI; Culpepper L; Fayyad RS; Musgnung J; Guico-Pabia CJ
Int Clin Psychopharmacol; 2013 Nov; 28(6):312-21. PubMed ID: 23881185
[TBL] [Abstract][Full Text] [Related]
15. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment.
Weisler RH; Ota A; Tsuneyoshi K; Perry P; Weiller E; Baker RA; Sheehan DV
J Affect Disord; 2016 Nov; 204():40-7. PubMed ID: 27322768
[TBL] [Abstract][Full Text] [Related]
16. Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.
Katzman MA; Nierenberg AA; Wajsbrot DB; Meier E; Prieto R; Pappadopulos E; Mackell J; Boucher M
J Clin Psychopharmacol; 2017 Oct; 37(5):555-561. PubMed ID: 28817491
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review.
Lee Y; Rosenblat JD; Lee J; Carmona NE; Subramaniapillai M; Shekotikhina M; Mansur RB; Brietzke E; Lee JH; Ho RC; Yim SJ; McIntyre RS
J Affect Disord; 2018 Feb; 227():406-415. PubMed ID: 29154157
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo.
Clayton AH; Reddy S; Focht K; Musgnung J; Fayyad R
J Sex Med; 2013 Mar; 10(3):768-76. PubMed ID: 22905811
[TBL] [Abstract][Full Text] [Related]
19. Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine.
Soares CN; Zhang M; Boucher M
CNS Spectr; 2019 Jun; 24(3):322-332. PubMed ID: 29140227
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
